UID:
almafu_9959013977502883
Format:
1 online resource (VII, 360 p. 70 illus., 65 illus. in color.)
Edition:
1st ed. 2019.
ISBN:
3-030-00362-0
Series Statement:
Hematologic Malignancies,
Content:
This book summarizes current knowledge of the biology and molecular pathogenesis of aggressive lymphomas and reviews the state of the art in diagnostic and therapeutic strategies. The aim is both to provide the reader with a sound understanding of the very significant progress that has been achieved in the understanding and management of these malignancies over recent years and to facilitate appropriate choice of the therapeutic strategy in individual cases. The assessment of different prognostic parameters are clearly presented in order to permits effective risk stratification that impacts on treatment choice. Recent insights into lymphomagenesis are exemplified and may assist in identifying emerging therapeutic targets. The comprehensive and up-to-date nature of the book will make it an ideal reference for all physicians and researchers interested in lymphoma, including clinicians from various medical specialties, biologists, pathologists, radiologists and nuclear medicine specialist, as well as students.
Note:
PART I: Epidemiology, Pathology and molecular Pathogenesis: Epidemiology -- Pathology and molecular pathogenesis of DLBCL and related entities -- Pathology and molecular pathogenesis of Burkitt lymphoma and lymphoblastic lymphoma -- Pathology and molecular pathogenesis of T-cell lymphoma -- Part III: Future directions in aggressive lymphomas: Role of modern imaging in aggressive lymphoma -- Kinase inhibitors -- Immunologic approaches -- Other novel targeted therapies -- How biology will help guiding our treatment decisions?.
Additional Edition:
ISBN 3-030-00361-2
Language:
English
DOI:
10.1007/978-3-030-00362-3
